Zhang X - Search Results

1

Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition.

Zhang X, Jones DR, Hall SD. Zhang X, et al. Drug Metab Dispos. 2009 Jan;37(1):150-60. doi: 10.1124/dmd.108.022178. Epub 2008 Oct 14. Drug Metab Dispos. 2009. PMID: 18854379

2

Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.

Zhang X, Quinney SK, Gorski JC, Jones DR, Hall SD. Zhang X, et al. Drug Metab Dispos. 2009 Aug;37(8):1587-97. doi: 10.1124/dmd.109.026658. Epub 2009 May 6. Drug Metab Dispos. 2009. PMID: 19420129 Clinical Trial.

3

Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.

Zhang X, Galinsky RE, Kimura RE, Quinney SK, Jones DR, Hall SD. Zhang X, et al. Drug Metab Dispos. 2010 Jan;38(1):61-72. doi: 10.1124/dmd.109.028290. Drug Metab Dispos. 2010. PMID: 19797607

4

Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.

Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, Hall SD. Quinney SK, et al. Among authors: zhang x. Drug Metab Dispos. 2010 Feb;38(2):241-8. doi: 10.1124/dmd.109.028746. Epub 2009 Nov 2. Drug Metab Dispos. 2010. PMID: 19884323 Free PMC article.

5

Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib.

Posada MM, Cannady EA, Payne CD, Zhang X, Bacon JA, Pak YA, Higgins JW, Shahri N, Hall SD, Hillgren KM. Posada MM, et al. Among authors: zhang x. Clin Transl Sci. 2017 Nov;10(6):509-519. doi: 10.1111/cts.12486. Epub 2017 Jul 27. Clin Transl Sci. 2017. PMID: 28749581 Free PMC article. Clinical Trial.

6

Gatifloxacin pharmacokinetics in healthy men and women.

Zhang X, Overholser BR, Kays MB, Sowinski KM. Zhang X, et al. J Clin Pharmacol. 2006 Oct;46(10):1154-62. doi: 10.1177/0091270006291840. J Clin Pharmacol. 2006. PMID: 16988204 Clinical Trial.

7

Occupancy of Nociceptin/Orphanin FQ Peptide Receptors by the Antagonist LY2940094 in Rats and Healthy Human Subjects.

Raddad E, Chappell A, Meyer J, Wilson A, Ruegg CE, Tauscher J, Statnick MA, Barth V, Zhang X, Verfaille SJ. Raddad E, et al. Among authors: zhang x. Drug Metab Dispos. 2016 Sep;44(9):1536-42. doi: 10.1124/dmd.116.070359. Epub 2016 Jun 27. Drug Metab Dispos. 2016. PMID: 27353045

8

Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose Once-Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo-Controlled Study.

Zhao X, Sheng XY, Payne CD, Zhang X, Wang F, Cui YM. Zhao X, et al. Among authors: zhang x. Clin Pharmacol Drug Dev. 2020 Nov;9(8):952-960. doi: 10.1002/cpdd.868. Epub 2020 Sep 17. Clin Pharmacol Drug Dev. 2020. PMID: 32945153 Free PMC article. Clinical Trial.

9

Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.

Zhang X, Chua L, Ernest C 2nd, Macias W, Rooney T, Tham LS. Zhang X, et al. CPT Pharmacometrics Syst Pharmacol. 2017 Dec;6(12):804-813. doi: 10.1002/psp4.12251. Epub 2017 Oct 17. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 28891251 Free PMC article. Clinical Trial.

10

Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.

Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, Montealegre Sanchez GA, de Jesus AA, Huang Y, Tsai WL, Gadina M, Prakash A, Janes JM, Zhang X, Macias WL, Kumar P, Goldbach-Mansky R. Kim H, et al. Among authors: zhang x. Clin Pharmacol Ther. 2018 Aug;104(2):364-373. doi: 10.1002/cpt.936. Epub 2017 Dec 8. Clin Pharmacol Ther. 2018. PMID: 29134648 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

183,232 results

Search Page

Filters